Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | ACP1 | P24666 | 3/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | NQO2 | P16083 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PPM1D | O15297 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20809129 | 0.86 | ACP1 (0.42) | RAB9AALDH1A1ACP1HTR6NPC1 | |
| SCHEMBL20809034 | 0.85 | HTR6 (0.43) | RAB9AALDH1A1ACP1HTR6P2RX7 | |
| SCHEMBL20809134 | 0.83 | ACHE (0.50) | RAB9AALDH1A1ACP1MEN1KMT2A | |
| SCHEMBL19258275 | 0.82 | ACP1 (0.44) | RAB9AALDH1A1ACP1HTR6NPC1 | |
| SCHEMBL20809365 | 0.77 | L3MBTL1 (0.47) | RAB9AALDH1A1ACP1P2RX7MEN1 | |
| SCHEMBL20809421 | 0.77 | HTR6 (0.45) | RAB9AALDH1A1ACP1HTR6NPC1 | |
| SCHEMBL20809080 | 0.76 | L3MBTL1 (0.49) | RAB9AALDH1A1ACP1P2RX7NPC1 | |
| SCHEMBL26613601 | 0.76 | CYP2C9 (0.48) | RAB9AP2RX7MEN1KMT2ANQO2 | |
| SCHEMBL20809032 | 0.75 | KCNH2 (0.44) | RAB9AALDH1A1HTR6 | |
| SCHEMBL20809130 | 0.75 | ACP1 (0.49) | RAB9AALDH1A1ACP1NPC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11692132-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2023-07-04 | — | — | US | disclosed |
| US-10957869-B2 | Organic luminescent materials containing cycloalkyl ancillary ligands | Beijing Summer Sprout Technology Co., Ltd. (CN) | 2021-03-23 | — | — | US | disclosed |
| US-20190103574-A1 | ORGANIC LUMINESCENT MATERIALS CONTAINING CYCLOALKYL ANCILLARY LIGANDS | Beijing Summer Sprout Technology Co., Ltd. (CN) | 2019-04-04 | — | — | US | disclosed |
| US-20190077818-A1 | ORGANIC LUMINESCENT MATERIALS CONTAINING FLUORINE ANCILLARY LIGANDS | Beijing Summer Sprout Technology Co., Ltd. (CN) | 2019-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190103574-A1 | ORGANIC LUMINESCENT MATERIALS CONTAINING CYCLOALKYL ANCILLARY LIGANDS | ACAT1, ACACA, ACAT2 | RAB9A 4437/4885ALDH1A1 42/4885ACP1 2963/4885 |
| US-10957869-B2 | Organic luminescent materials containing cycloalkyl ancillary ligands | ACAT1, ACACA, ACAT2 | RAB9A 4437/4885ALDH1A1 42/4885ACP1 2963/4885 |
| US-20190077818-A1 | ORGANIC LUMINESCENT MATERIALS CONTAINING FLUORINE ANCILLARY LIGANDS | FOXO1, NAA15, FOXK1 | RAB9A 3706/4885ALDH1A1 16/4885ACP1 3989/4885 |
| US-11692132-B2 | Organic electroluminescent materials and devices | OSBP, OCIAD1, OCIAD2 | RAB9A 1840/4885ALDH1A1 1821/4885ACP1 1019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.